title: Recurrent pyoderma gangrenosum and cystic acne associated with leucocyte adhesion deficiency due to novel mutations in ITGB2: successful treatment with infliximab and adalimumab.
authors.affiliation: Department of Medical Sciences/Dermatology, Uppsala University, SE-751 85 Uppsala, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Vahlquist
authors.forename: Lena Douhan
authors.initials: LD
authors.lastname: Håkansson
authors.forename: Lars
authors.initials: L
authors.lastname: Rönnblom
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Karawajczyk
authors.forename: Anders
authors.initials: A
authors.lastname: Fasth
authors.forename: Marielle E
authors.initials: ME
authors.lastname: van Gijn
authors.forename: Dirk
authors.initials: D
authors.lastname: Roos
authors.forename: Per
authors.initials: P
authors.lastname: Venge
mesh_terms: D000152:Acne Vulgaris / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D018821:CD18 Antigens / Q000235:genetics*; D003560:Cysts / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D004359:Drug Therapy, Combination; D020022:Genetic Predisposition to Disease; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab / Q000627:therapeutic use*; D018370:Leukocyte-Adhesion Deficiency Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D009154:Mutation; D010641:Phenotype; D017511:Pyoderma Gangrenosum / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D012008:Recurrence; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D018821:CD18 Antigens; D007166:Immunosuppressive Agents; D000069285:Infliximab; D000068879:Adalimumab